Activated 4E-BP1 represses tumourigenesis and IGF-I-mediated activation of the eIF4F complex in mesothelioma

British Journal of Cancer

Volumn 101, Issue 3, 2009, Pages 424-431

  Jacobson, B A ^a,b   De, A ^c   Kratzke, M G ^b   Patel, M R ^a   Jay Dixon, J ^a   Whitson, B A ^a   Sadiq, A A ^a   Bitterman, P B ^a   Polunovsky, V A ^a   Kratzke, R A ^a,b  

^a UNIVERSITY OF MINNESOTA MEDICAL SCHOOL   (United States)

^b VETERANS AFFAIRS MEDICAL CENTER   (United States)

^c UNIVERSITY OF MINNESOTA   (United States)

Author keywords

4E BP1; Cap dependent; EIF4E; EIF4F; IGF I; Translation

Indexed keywords

1,4 DIAMINO 1,4 BIS(2 AMINOPHENYLTHIO) 2,3 DICYANOBUTADIENE; 2 MORPHOLINO 8 PHENYLCHROMONE; 7 METHYLGUANOSINE TRIPHOSPHATE; GUANOSINE TRIPHOSPHATE DERIVATIVE; INITIATION FACTOR 4E; INITIATION FACTOR 4E BINDING PROTEIN 1; MITOGEN ACTIVATED PROTEIN KINASE; PROTEIN KINASE B; REPRESSOR PROTEIN; SOMATOMEDIN C; UNCLASSIFIED DRUG;

ARTICLE; BINDING ASSAY; CARCINOGENESIS; CELL ACTIVATION; CELL GROWTH; CELL MOTILITY; CELL PROLIFERATION; COLONY FORMATION; CONTROLLED STUDY; HUMAN; HUMAN CELL; MESOTHELIOMA; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION; RNA TRANSLATION; SIGNAL TRANSDUCTION; TRANSCRIPTION INITIATION SITE; TRANSLATION INITIATION; TRANSLATION REGULATION; XENOGRAFT;

1-PHOSPHATIDYLINOSITOL 3-KINASE; ADAPTOR PROTEINS, SIGNAL TRANSDUCING; ANIMALS; CARRIER PROTEINS; CELL LINE, TUMOR; CHROMONES; EUKARYOTIC INITIATION FACTOR-4F; HUMANS; INSULIN-LIKE GROWTH FACTOR I; MESOTHELIOMA; MICE; MORPHOLINES; NEOPLASM TRANSPLANTATION; PHOSPHOPROTEINS; PROTEIN BIOSYNTHESIS; PROTO-ONCOGENE PROTEINS C-AKT; RECEPTOR, IGF TYPE 1; RNA CAP-BINDING PROTEINS; RNA CAPS; SIGNAL TRANSDUCTION; TRANSPLANTATION, HETEROLOGOUS;

EID: 68149161618     PISSN: 00070920     EISSN: 15321827     Source Type: Journal    
DOI: 10.1038/sj.bjc.6605184     Document Type: Article

References (27)

1. Britton M (2002) The epidemiology of mesothelioma. Semin Oncol 29: 18-25
2. De Benedetti A, Graff JR (2004) eIF-4E expression and its role in malignancies and metastases. Oncogene 23: 3189-3199
3. Gingras AC, Raught B, Gygi SP, Niedzwiecka A, Miron M, Burley SK, Polakiewicz RD, Wyslouch-Cieszynska A, Aebersold R, Sonenberg N (2001) Hierarchical phosphorylation of the translation inhibitor 4E-BP1. Genes Dev 15: 2852-2864
4. Graff JR, Konicek BW, Carter JH, Marcusson EG (2008) Targeting the eukaryotic translation initiation factor 4E for cancer therapy. Cancer Res 68: 631-634
5. Graff JR, Konicek BW, Vincent TM, Lynch RL, Monteith D, Weir SN, Schwier P, Capen A, Goode RL, Dowless MS, Chen Y, Zhang H, Sissons S, Cox K, McNulty AM, Parsons SH, Wang T, Sams L, Geeganage S, Douglass LE, Neubauer BL, Dean NM, Blanchard K, Shou J, Stancato LF, Carter JH, Marcusson EG (2007) Therapeutic suppression of translation initiation factor eIF4E expression reduces tumor growth without toxicity. J Clin Invest 117: 2638-2648
6. Graff JR, Zimmer SG (2003) Translational control and metastatic progression: enhanced activity of the mRNA cap-binding protein eIF-4E selectively enhances translation of metastasis-related mRNAs. Clin Exp Metastasis 20: 265-273
7. Guix M, Faber AC, Wang SE, Olivares MG, Song Y, Qu S, Rinehart C, Seidel B, Yee D, Arteaga CL, Engelman JA (2008) Acquired resistance to EGFR tyrosine kinase inhibitors in cancer cells is mediated by loss of IGF-binding proteins. J Clin Invest 118: 2609-2619
8. Haddad T, Yee D (2006) Targeting the insulin-like growth factor axis as a cancer therapy. Future Oncol 2: 101-110
9. Hoang CD, D'Cunha J, Kratzke MG, Casmey CE, Frizelle SP, Maddaus MA, Kratzke RA (2004a) Gene expression profiling identifies matriptase overexpression in malignant mesothelioma. Chest 125: 1843-1852
10. Hoang CD, Zhang X, Scott PD, Guillaume TJ, Maddaus MA, Yee D, Kratzke RA (2004b) Selective activation of insulin receptor substrate-1 and -2 in pleural mesothelioma cells: association with distinct malignant pheno-types. Cancer Res 64: 7479-7485
11. Jacobson BA, Alter MD, Kratzke MG, Frizelle SP, Zhang Y, Peterson MS, Avdulov S, Mohorn RP, Whitson BA, Bitterman PB, Polunovsky VA, Kratzke RA (2006) Repression of cap-dependent translation attenuates the transformed phenotype in non-small cell lung cancer both in vitro and in vivo. Cancer Res 66: 4256-4262
12. Jerome L, Shiry L, Leyland-Jones B (2003) Deregulation of the IGF axis in cancer: epidemiological evidence and potential therapeutic interventions. Endocr Relat Cancer 10: 561-578
13. Kratzke RA, Otterson GA, Lincoln CE, Ewing S, Oie H, Geradts J, Kaye FJ (1995) Immunohistochemical analysis of the p16INK4 cyclin-dependent kinase inhibitor in malignant mesothelioma. J Natl Cancer Inst 87: 1870-1875
14. Lee AY, Raz DJ, He B, Jablons DM (2007) Update on the molecular biology of malignant mesothelioma. Cancer 109: 1454-1461
15. Lee TC, Zhang Y, Aston C, Hintz R, Jagirdar J, Perle MA, Burt M, Rom WN (1993) Normal human mesothelial cells and mesothelioma cell lines express insulin-like growth factor I and associated molecules. Cancer Res 53: 2858-2864
16. Mamane Y, Petroulakis E, Rong L, Yoshida K, Ler LW, Sonenberg N (2004) eIF4E-from translation to transformation. Oncogene 23: 3172-3179
17. Miller BS, Yee D (2005) Type I insulin-like growth factor receptor as a therapeutic target in cancer. Cancer Res 65: 10123-10127
18. Pass HI, Mew DJ, Carbone M, Matthews WA, Donington JS, Baserga R, Walker CL, Resnicoff M, Steinberg SM (1996) Inhibition of hamster mesothelioma tumorigenesis by an antisense expression plasmid to the insulin-like growth factor-1 receptor. Cancer Res 56: 4044-4048
19. Patel MR, Jacobson BA, De A, Frizelle SP, Janne P, Thumma SC, Whitson BA, Farassati F, Kratzke RA (2007) Ras pathway activation in malignant mesothelioma. J Thorac Oncol 2: 789-795
20. Polunovsky VA, Bitterman PB (2006) The cap-dependent translation apparatus integrates and amplifies cancer pathways. RNA Biol 3: 10-17
21. Prevot D, Darlix JL, Ohlmann T (2003) Conducting the initiation of protein synthesis: the role of eIF4G. Biol Cell 95: 141-156
22. Rajasekhar VK, Viale A, Socci ND, Wiedmann M, Hu X, Holland EC (2003) Oncogenic Ras and Akt signaling contribute to glioblastoma formation by differential recruitment of existing mRNAs to polysomes. Mol Cell 12: 889-901
23. Sachdev D, Yee D (2006) Inhibitors of insulin-like growth factor signaling: a therapeutic approach for breast cancer. J Mammary Gland Biol Neoplasia 11: 27-39
24. Thumma SC, Kratzke RA (2007) Translational control: a target for cancer therapy. Cancer Lett 258: 1-8
25. Whitson BA, Jacobson BA, Frizelle S, Patel MR, Yee D, Maddaus MA, Kratzke RA (2006) Effects of insulin-like growth factor-1 receptor inhibition in mesothelioma. Thoracic Surgery Directors Association Resident Research Award. Ann Thorac Surg 82: 996-1001; discussion 1001-2
26. Whitson BA, Kratzke RA (2006) Molecular pathways in malignant pleural mesothelioma. Cancer Lett 239: 183-189
27. Workman P, Twentyman P, Balkwill F, Balmain A, Chaplin D, Double J, Embleton J, Newell D, Raymond R, Stables J, Stephens T, Wallace J (1998) United Kingdom Co-ordinating Committee on Cancer Research (UKCCCR) Guidelines for the welfare of animals in experimental neoplasia (second edition). Br J Cancer 77: 1-10